$15.35
6.75% yesterday
Nasdaq, Dec 04, 10:00 pm CET
ISIN
IE000GID8VI0
Symbol
GHRS

GH Research PLC Stock price

$15.35
+1.85 13.70% 1M
+2.92 23.49% 6M
+8.35 119.29% YTD
+7.35 91.88% 1Y
+3.95 34.65% 3Y
-3.90 20.26% 5Y
-3.90 20.26% 10Y
-3.90 20.26% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
+0.97 6.75%
ISIN
IE000GID8VI0
Symbol
GHRS
Industry

Key metrics

Basic
Market capitalization
$892.0m
Enterprise Value
$604.0m
Net debt
positive
Cash
$288.5m
Shares outstanding
62.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.1
Financial Health
Equity Ratio
95.1%
Return on Equity
-21.8%
ROCE
-19.5%
ROIC
-1,641.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-56.6m | $-59.6m
EBIT
$-56.9m | $-62.3m
Net Income
$-42.9m | $-53.4m
Free Cash Flow
$-41.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-54.0% | -19.2%
EBIT
-53.9% | -23.9%
Net Income
-27.1% | -37.0%
Free Cash Flow
-4.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.7
FCF per Share
$-0.7
Short interest
9.8%
Employees
50
Rev per Employee
$0.0
Show more

Is GH Research PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

GH Research PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a GH Research PLC forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a GH Research PLC forecast:

Buy
93%
Hold
7%

Financial data from GH Research PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
103% 103%
-
- Research and Development Expense 36 36
36% 36%
-
-57 -57
54% 54%
-
- Depreciation and Amortization 0.33 0.33
38% 38%
-
EBIT (Operating Income) EBIT -57 -57
54% 54%
-
Net Profit -43 -43
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about GH Research PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GH Research PLC Stock News

Neutral
GlobeNewsWire
28 days ago
Engagement with FDA on GH001 IND complete response ongoing Full dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025 Long-term clinical data on safety and efficacy from Open-Label Extension presented at ECNP in October 2025 Cash, cash equivalents and marketable securities of $293.9 million as of September 30, 2025 DUBLIN, Nov. 06, 2025 (GLOBE NEWSWIRE) -- GH Research P...
Neutral
GlobeNewsWire
about 2 months ago
DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the N...
Neutral
GlobeNewsWire
4 months ago
Global pivotal program initiation on track for 2026 Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapy Treatment was well tolerated and no treatment related serious adverse events were reported. There was no evidence of treatment-emergent suic...
More GH Research PLC News

Company Profile

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Dr. Valcheva
Employees 50
Founded 2021
Website www.ghres.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today